Recent 8-K filings for EBRCZ

• April 9, 2026, 7:59 PM ET earnings materiality 0.60 positive item 2.02item 9.01 ◈ Earnings Releases

  EBR Systems Q1 preliminary revenue $2.25-$2.36M; commercial cases double QoQ

  Preliminary unaudited Q1 2026 revenue $2.25M-$2.36M; financial close not yet complete.

• March 13, 2026, 7:59 PM ET other material materiality 0.70 neutral item 5.07

  EBR Systems shareholders approve reverse stock split (1:5-1:20) and 55.9M CDI issuance

  Reverse stock split proposal passed with 233.2M for, 970K against; board may set ratio 1:5 to 1:20 or abandon.

• January 13, 2026, 6:59 PM ET earnings materiality 0.70 positive item 2.02item 9.01

  EBR Systems reports Q4 2025 preliminary rev ~$900K; WiSE implants double QoQ, clinical studies advance

  Preliminary Q4 revenue $870K-$935K; FY2025 revenue $1,552K-$1,617K (unaudited, subject to audit adjustments).

• May 29, 2025, 7:59 PM ET other material materiality 0.60 neutral item 1.01item 3.02item 9.01

  EBR Systems raises ~$36M via 55.9M CDI placement at A$1.00 per CDI

  Issued 55.9M CDIs at A$1.00 (~US$0.6434), raising ~US$36M gross before ~$2.25M fees.

• April 15, 2025, 7:59 PM ET regulatory materiality 0.80 positive item 8.01item 9.01

  CMS proposes NTAP reimbursement for EBR's WiSE CRT at max 65% rate

  CMS proposed NTAP for WiSE CRT System for FY 2026 at maximum add-on payment of 65% of device cost.

• April 14, 2025, 7:59 PM ET regulatory materiality 0.90 positive item 8.01item 9.01

  FDA approves EBR Systems' WiSE CRT System for commercial distribution in US

  FDA approved WiSE CRT System for left ventricular endocardial pacing; target initial US addressable market ~$3.6B.

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.90 · Median 0.60 · Most common event other_material

4 positive 0 negative 6 neutral

source · EBRCZ on sec.gov